文献速递中药与中成药合理使用中医内科

中成药防治放化疗口腔黏膜炎的系统评价与meta分析

Efficacy and Safety of Chinese Patent Medicine for the Prevention and Treatment of Radiotherapy and Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.
PubMed 文献 · Front Pharmacol · 2022-03-28

该系统评价与meta分析纳入27项随机对照试验共2312例,评估中成药预防和治疗放化疗所致口腔黏膜炎的有效性与安全性。结果显示,预防方面中成药可显著降低口腔黏膜炎发生率(尤其严重类型)并减轻疼痛(p<0.05);治疗方面可缓解症状、促进溃疡愈合、提高临床有效率(p<0.05)。不良反应主要为胃肠道反应和苦味,未见严重不良事件。

要点

  • 中成药预防放化疗口腔黏膜炎可降低发生率,尤其减少严重类型并减轻疼痛。
  • 中成药治疗放化疗口腔黏膜炎可缓解症状、促进溃疡愈合、提高临床有效率。
  • 不良反应以胃肠道反应和苦味为主,无严重不良事件报告。

核心结论

  • 中成药可能通过降低发生率、减少严重类型、缓解症状和促进溃疡愈合来防治放化疗所致口腔黏膜炎。
  • 因纳入研究数量有限和发表偏倚,未来仍需更多高质量双盲安慰剂对照随机对照试验验证。

研究设计与样本

  • 系统评价与meta分析,检索10个数据库(建库至2021年8月)的随机对照试验。
  • 共纳入27项随机对照试验,合计2312例病例。
  • 采用Cochrane手册评估研究质量与偏倚,使用Review Manager 5.4.1软件进行meta分析。

主要发现

  • 预防方面,中成药可显著降低放化疗口腔黏膜炎发生率(尤其严重类型)并减轻疼痛水平(p<0.05)。
  • 治疗方面,中成药可缓解症状、促进溃疡愈合、提高临床治疗有效率(p<0.05)。
  • 亚组分析结果主要与上述结果一致。
  • 不良反应主要包括胃肠道反应和苦味,未见严重不良事件报告。

关键数值与推荐

  • 结局指标包括放化疗口腔黏膜炎的发生率、疼痛水平、严重程度、有效率及不良反应。
  • 多数研究被评为低或不明确偏倚风险。

临床怎么用

  • 临床可考虑将中成药作为放化疗口腔黏膜炎的辅助防治手段,尤其用于预防严重类型和减轻疼痛。
  • 使用中需关注胃肠道反应和苦味等不良反应,目前未见严重不良事件报告。

局限性

  • 符合条件的研究数量有限。
  • 存在发表偏倚。
  • 未来需更多高质量、双盲、安慰剂对照随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Radiotherapy and chemotherapy-induced oral mucositis can affect cancer patients' quality of life, even necessitate cancer therapy and influence prognosis. Chinese patent medicines (CPMs) have been widely used as complementary alternative medicines for the prevention and treatment of oral mucositis, and their efficacy and safety require further evaluation. Therefore, this study was conducted to provide references for clinical practice. Methods: Ten databases were searched electronically and manually to identify randomized controlled trials (RCTs) from their inception to August 2021, concerning the prevention and treatment of radiotherapy and chemotherapy-induced oral mucositis with CPMs. The prevalence, pain level, and the severity of radiotherapy and chemotherapy-induced oral mucositis, as well as the effectiveness rate and adverse effects of CPMs, were set as the outcome criteria. The assessment criteria of the Cochrane Handbook were used to determine study quality and bias, and meta-analysis was conducted using Review Manager 5.4.1 software. Results: A total of 2,312 cases from 27 RCTs were included. Most studies were considered to have a low or unclear risk of bias. More research is available on the use of CPMs in the prevention of radiotherapy and chemotherapy-induced oral mucositis than in its treatment. As for the prevention, it was proved that CPMs could significantly reduce the prevalence of radiotherapy and chemotherapy-induced oral mucositis, especially for the severe types, and decrease pain levels (p < 0.05). For treatment, CPMs could alleviate the symptoms, promote the healing of ulceration in radiotherapy and chemotherapy-induced oral mucositis, and thus improve the efficiency of clinical treatment (p < 0.05). The results of subgroup analyses were mainly consistent with the above results. The adverse effects of CPMs mainly included gastrointestinal reactions and bitter taste, and no serious adverse events were reported. Conclusions: This systematic review and meta-analysis indicated CPMs might be effective for the prevention and treatment of radiotherapy and chemotherapy-induced oral mucositis through reducing the prevalence, decreasing the occurrence of severe types, alleviating the symptoms, and promoting the healing of ulceration. However, due to the limited number of eligible studies and the publication bias, more high-quality, double-blinded, placebo-controlled RCTs are still needed in future research. Systematic Review Registration: [https://inplasy.com/], identifier [INPLASY2021100100].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xie Y, Fang X, Hua H, et al. Efficacy and Safety of Chinese Patent Medicine for the Prevention and Treatment of Radiotherapy and Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022. PMID: 35418855. doi:10.3389/fphar.2022.812085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。